Compound News and Research

RSS

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Henry Schein fourth quarter net sales increase 15.1% to $7.5 billion

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended December 25, 2010.

22 Feb 2011

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer.

22 Feb 2011

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

A group of chemical compounds used by a species of tropical seaweed to ward off fungus attacks may have promising antimalarial properties for humans. The compounds are part of a unique chemical signaling system that seaweeds use to battle enemies - and that may provide a wealth of potential new pharmaceutical compounds.

22 Feb 2011

RegeneRx listed on MDB’s 'Best & Brightest' innovators for 2011

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been included on MDB Capital Group's "Best & Brightest" innovators list of 150 companies for 2011. Criterion for inclusion is a ranking in the 90th percentile for technology leadership from more than 1,500 companies with U.S. patents granted, as rated by PatentVest®, MDB's proprietary, intellectual property (IP), business intelligence database.

19 Feb 2011

Crustacean inspired technology leads to better calcium supplements

Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.

19 Feb 2011

New method to help unravel structural mysteries of nature

The team of Professor Burkhard Luy from KIT and Junior Professor Stefan F. Kirsch from the TUM has now shown for the first time that certain NMR parameters, the so-called residual dipolar couplings, can make a significant contribution towards determining the constitution of chemical compounds when traditional methods fail.

18 Feb 2011

Scientists investigate natural chemical compound in sea sponges to create novel anti-cancer drugs

Scientists in London are turning to sea sponges to help them learn more about anti-cancer drugs. Using his £106,079 grant from the Association for International Cancer Research Dr Matthew Fuchter and his team are investigating a naturally-occurring chemical found in the sea sponge.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Skeleton regulates fertility in males, but not females

Researchers at Columbia University Medical Center have discovered that the skeleton acts as a regulator of fertility in male mice through a hormone released by bone, known as osteocalcin.

17 Feb 2011

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

University of Tennessee, Knoxville, researchers have found that blue-green algae may be responsible for producing an estrogen-like compound in the environment which could disrupt the normal activity of reproductive hormones and adversely affect fish, plants and human health.

17 Feb 2011

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences, a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of a new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products.

17 Feb 2011

U.S. Patent Office issues Notice of Allowance to Biomoda's CyPath assay for cancer detection

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent application on a quantitative method for scoring cells labeled with the CyPath assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

17 Feb 2011

Ban called for allegedly carcinogenic caramel component in sodas

A consumer advocacy group has urged the U.S. Food and Drug Administration (FDA) this Wednesday to ban some chemically enhanced caramel food colorings used in widely consumed cola drinks as they could cause cancer.

16 Feb 2011

Baldness cure by serendipity

Scientists at the University of California, Los Angeles were studying gut function but accidentally stumbled upon a five-day treatment that restored natural fur on bald laboratory mice.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

Viral Genetics' lead researcher, Advisor to receive Lauren F. Brooks Hope Award

Viral Genetics, Inc. announced today that lead researcher Dr. M. Karen Newell Rogers and Advisor Mr. Richard Gerstner will receive the Lauren F. Brooks Hope Award, presented by Time for Lyme, Inc.

16 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

Compound News and Research

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Henry Schein fourth quarter net sales increase 15.1% to $7.5 billion

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

RegeneRx listed on MDB’s 'Best & Brightest' innovators for 2011

Crustacean inspired technology leads to better calcium supplements

New method to help unravel structural mysteries of nature

Scientists investigate natural chemical compound in sea sponges to create novel anti-cancer drugs

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Skeleton regulates fertility in males, but not females

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

ACEA Biosciences receives new U. S. Patent for chemical compound screening

U.S. Patent Office issues Notice of Allowance to Biomoda's CyPath assay for cancer detection

Ban called for allegedly carcinogenic caramel component in sodas

Baldness cure by serendipity

CTI's fourth quarter net loss increases to $34.1 million

Viral Genetics' lead researcher, Advisor to receive Lauren F. Brooks Hope Award

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News